Strategic Collaboration for Advanced Antibody Discovery
Alloy Therapeutics Inc., a biotechnology ecosystem company, has announced a new strategic collaboration with Pfizer Inc. The partnership aims to develop an innovative platform for antibody discovery. This platform aims to enhance Pfizer’s ability to target complex and difficult-to-address proteins with highly potent and specific antibodies.
Financial Terms and Collaboration Scope
Under the agreement, Alloy will receive an upfront payment from Pfizer. It will also be eligible for milestone payments from preclinical to commercial stages for products originating from the platform.
Expanding an Established Partnership
As reported by medicaldialogues.in, Heather Schwoebel highlighted the ongoing collaboration between the companies. She is the Chief Business Officer for Antibodies and Head of Strategic Collaborations at Alloy. “Pfizer has used our industry-leading ATX-Gx platform for years. We worked closely to develop the common light chain ATX-CLC strains.” This collaboration underscores how pharma companies can leverage Alloy’s technology and expertise to drive antibody discovery and innovation,” she said. “Now, we will apply our expertise to create a new platform that enhances Pfizer’s antibody development against high-value, challenging targets. We are excited to expand our partnership in the fight against disease.”
Industry Leadership in Transgenic Mice Platforms
Alloy’s ATX-Gx platform has rapidly become the standard for fully humanized transgenic mice, with over 170 partners utilizing it for therapeutic discovery. The company reinvests its revenue into continuous innovation, leading to the expansion of its murine platforms. These include the ATX-GL strain, featuring a full human lambda repertoire, and the ATX-GKH hyperimmune strain, designed to enhance antigen-specific B-cell generation and IgG class switching.
Enhancing Bispecific Antibody Discovery
Pfizer and Alloy have previously collaborated on various antibody discovery projects, including the ATX-CLC platform. Launched in 2023, this platform enables the expression of common light chain antibodies while maintaining full heavy chain diversity, streamlining the discovery of modular bispecific antibodies. Researchers can access it through Alloy’s Antibody Discovery Services unit.
Driving Innovation in Drug Discovery
Davide Schiavone, Head of Genetically Engineered Organisms at Alloy Therapeutics, emphasized the company’s leadership in transgenic animal model development. “Our Cambridge, UK research team has created a cutting-edge workflow for generating transgenic animal models, reinforcing our position in drug discovery. By collaborating with industry leaders like Pfizer, we ensure our platforms meet real scientific needs—solutions that simplify and accelerate the drug discovery process,” he said. “Our commitment to innovation is deeply rooted in collaboration, and we believe the best way to create future technologies is by developing them alongside our partners.”